Print page |
Email page
| 
Download PDF
« Previous Release | Next Release »
CAMBRIDGE, Mass., Apr 16, 2008 (BUSINESS WIRE) -- Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, has appointed John C. Taylor as Vice President, Business Development. Mr. Taylor will report to Javelin's recently appointed CEO Martin J. Driscoll and will be responsible for daily execution of Javelin's global partnership initiatives for its late stage product pipeline.
"I have placed a high priority on Business Development initiatives as a strategic element of Javelin's new commercialization strategy. Our first commercial partnership will be structured to accelerate the market uptake for our brand, reduce our exposure to early commercialization risk, and augment our growth capital while providing future upside. John will play an essential role in assisting us as we complete this effort," said Martin Driscoll, Chief Executive Officer.
Mr. Taylor will also work with Dr. Daniel B. Carr, CMO and Vice Chair and other members of Javelin's clinical team to identify and evaluate in-licensing opportunities that fit within Javelin's clinical development expertise and new commercialization strategy to build on its late stage pipeline of pain drug candidates.
About Mr. Taylor
Prior to joining Javelin, Mr. Taylor was Director of Business Development at Eurand, Inc. where he led the North American transaction team responsible for managing agreements involving the company's pipeline products and drug delivery technologies, Mr. Taylor also served as the Director of Business Development at Sarnoff Corporation where he led fundraising and commercialization activities for the Healthcare and Life Sciences Unit. At Amersham Pharmacia Biotech, Mr. Taylor worked in licensing and product management. Mr. Taylor began his career in a sales capacity at BioWittaker, Inc. Mr. Taylor graduated from Clemson University and holds a Masters degree from the University of Pennsylvania - Wharton School of Business.
About Javelin Pharmaceuticals, Inc.
With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has three drug candidates in US Phase 3 clinical development. One of these US Phase 3 drug candidates, Dyloject(TM), has received Marketing Authorization Application (MAA) approval and favorable pricing in the UK, where it is now being sold. Previous clinical trials have demonstrated its safety and rapid onset of action. For additional information about Javelin, please visit the company's website at http://www.javelinpharmaceuticals.com.
Forward Looking Statement
This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.
JAV-G
SOURCE: Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Investor Relations & Media Rick Pierce, 617-349-4500 VP, Investor Relations rpierce@javelinpharma.com or Corporate Communications June Gregg, 617-349-4500 jgregg@javelinpharma.com
Copyright Business Wire 2008
News Provided by COMTEX